Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Only 30-40% of patients diagnosed with HCC are candidates for curative treatment options. The remaining majority of patients undergo local, regional or systemic palliative therapies. Transvascular therapy of HCC takes advantag...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 Jan 2018
|
| In: |
Minimally invasive therapy & allied technologies
Year: 2018, Jahrgang: 27, Heft: 2, Pages: 69-80 |
| ISSN: | 1365-2931 |
| DOI: | 10.1080/13645706.2018.1432489 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1080/13645706.2018.1432489
|
| Verfasserangaben: | Daniel Gnutzmann, Nikolas Kortes, Migle Sumkauskaite, Anne Schmitz, Karl-Heinz Weiss, Boris Radeleff |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1664883681 | ||
| 003 | DE-627 | ||
| 005 | 20230426130858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190507s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13645706.2018.1432489 |2 doi | |
| 035 | |a (DE-627)1664883681 | ||
| 035 | |a (DE-599)KXP1664883681 | ||
| 035 | |a (OCoLC)1341212412 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gnutzmann, Daniel |e VerfasserIn |0 (DE-588)1034982540 |0 (DE-627)746586973 |0 (DE-576)382594665 |4 aut | |
| 245 | 1 | 0 | |a Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments |c Daniel Gnutzmann, Nikolas Kortes, Migle Sumkauskaite, Anne Schmitz, Karl-Heinz Weiss, Boris Radeleff |
| 264 | 1 | |c 30 Jan 2018 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.05.2019 | ||
| 520 | |a Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Only 30-40% of patients diagnosed with HCC are candidates for curative treatment options. The remaining majority of patients undergo local, regional or systemic palliative therapies. Transvascular therapy of HCC takes advantage of the fact that hypervascularized HCCs receive their main perfusion from the hepatic artery. In this context transvascular therapy describes different therapies: bland embolization (transarterial embolization, TAE), cTACE (conventional transarterial chemoembolization), DEB-TACE (TACE with drug-eluting beads, DEB) and SIRT (selective internal radiation therapy, radioembolization). cTACE is the most common type of transvascular treatment and represents a combination of the intra-arterial use of a chemotherapeutic agent and embolization. There is no standardized regimen for cTACE. It remains unclear whether the intra-arterial application of a chemotherapeutic agent is definitely required, because bland embolization alone using very small spherical particles shows tumor necrosis comparable to cTACE. For DEB-TACE microparticles loaded with a chemotherapeutic drug combine the advantages of cTACE and bland embolization. | ||
| 650 | 4 | |a Conventional TransArterial ChemoEmbolization | |
| 650 | 4 | |a drug-eluting beads | |
| 650 | 4 | |a embolization | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a Lipiodol | |
| 700 | 1 | |a Weiss, Karl Heinz |d 1976- |e VerfasserIn |0 (DE-588)130069531 |0 (DE-627)489615465 |0 (DE-576)297980203 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Minimally invasive therapy & allied technologies |d Abingdon : Taylor & Francis Group, 1996 |g 27(2018), 2, Seite 69-80 |h Online-Ressource |w (DE-627)342893971 |w (DE-600)2072609-0 |w (DE-576)097694924 |x 1365-2931 |7 nnas |a Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments |
| 773 | 1 | 8 | |g volume:27 |g year:2018 |g number:2 |g pages:69-80 |g extent:12 |a Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments |
| 856 | 4 | 0 | |u https://doi.org/10.1080/13645706.2018.1432489 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1080/13645706.2018.1432489 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190507 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 130069531 |a Weiss, Karl Heinz |m 130069531:Weiss, Karl Heinz |d 60000 |d 61300 |e 60000PW130069531 |e 61300PW130069531 |k 0/60000/ |k 1/60000/61300/ |p 5 | ||
| 999 | |a KXP-PPN1664883681 |e 347194964X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Daniel Gnutzmann, Nikolas Kortes, Migle Sumkauskaite, Anne Schmitz, Karl-Heinz Weiss, Boris Radeleff"]},"person":[{"role":"aut","roleDisplay":"VerfasserIn","given":"Daniel","family":"Gnutzmann","display":"Gnutzmann, Daniel"},{"given":"Karl Heinz","family":"Weiss","display":"Weiss, Karl Heinz","role":"aut","roleDisplay":"VerfasserIn"}],"language":["eng"],"title":[{"title_sort":"Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments","title":"Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments"}],"recId":"1664883681","note":["Gesehen am 07.05.2019"],"origin":[{"dateIssuedDisp":"30 Jan 2018","dateIssuedKey":"2018"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"language":["eng"],"title":[{"title":"Minimally invasive therapy & allied technologies","title_sort":"Minimally invasive therapy & allied technologies","subtitle":"the official journal of SMIT, the Society for Minimally Invasive Therapy"}],"recId":"342893971","note":["Gesehen am 08.09.15"],"titleAlt":[{"title":"MITAT"}],"disp":"Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developmentsMinimally invasive therapy & allied technologies","physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["5.1996 -"],"part":{"volume":"27","extent":"12","year":"2018","pages":"69-80","issue":"2","text":"27(2018), 2, Seite 69-80"},"origin":[{"dateIssuedDisp":"1996-","publisherPlace":"Abingdon ; London","dateIssuedKey":"1996","publisher":"Taylor & Francis Group ; Informa Healthcare"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"issn":["1365-2931"],"eki":["342893971"],"zdb":["2072609-0"]}}],"id":{"eki":["1664883681"],"doi":["10.1080/13645706.2018.1432489"]}} | ||
| SRT | |a GNUTZMANNDTRANSVASCU3020 | ||